Zacks Investment Research Upgrades Applied Genetic Technologies (NASDAQ: AGTC) to “Buy”

Advertisements

Applied Genetic Technologies (NASDAQ: AGTC – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Tuesday, Zacks.com reports. The brokerage presently has a $ 1.00 price target on the biotechnology company stock. Zacks Investment Research’s price target would suggest a potential upside of 19.08% from the company previous close.

According to Zacks, “Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. It develops gene therapy products for inherited orphan ophthalmology diseases. Its lead product candidates in the preclinical stage include treatments for X-linked retinoschisis, Achromatopsia, and X-linked retinitis pigmentosa, which are diseases of the eye caused by mutations in single genes. Applied Genetic Technologies Corporation is headquartered in Alachua, Florida. “

A number of other analysts also recently weighed in on the company. Cantor Fitzgerald reiterated an “overweight” rating on shares of Applied Genetic Technologies in a report on Tuesday, May 17th. Chardan Capital reiterated a “buy” rating on shares of Applied Genetic Technologies in a report on Monday, April 11th. StockNews.com started coverage on Applied Genetic Technologies in a research note on Thursday, March 31st. They issued a “sell” rating for the company. Roth Capital restated a “buy” rating on shares of Applied Genetic Technologies in a research note on Tuesday, February 8th. Finally, Stifel Nicolaus restated a “buy” rating and issued a $ 10.00 target price on shares of Applied Genetic Technologies in a research note on Thursday, April 14th. One investment analyst has rated the stock with a sell rating and eight have given a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $ 11.50.

Shares of AGTC traded down $ 0.02 during trading hours on Tuesday, reaching $ 0.84. The stock had a trading volume of 195,031 shares, compared to its average volume of 571,224. Applied Genetic Technologies has a 12 month low of $ 0.58 and a 12 month high of $ 4.65. The stock has a market capitalization of $ 42.60 million, a PE ratio of -0.58 and a beta of 1.65. The company has a debt-to-equity ratio of 0.24, a quick ratio of 3.13 and a current ratio of 2.73. The company 50-day moving average is $ 1.07 and its two-hundred day moving average is $ 1.70.

Several institutional investors have recently bought and sold shares of the business. Cantor Fitzgerald LP bought a new position in shares of Applied Genetic Technologies during the 1st quarter worth approximately $ 2,524,000. Vanguard Group Inc. increased its stake in shares of Applied Genetic Technologies by 14.4% during the 1st quarter. Vanguard Group Inc. now owns 1,981,565 shares of the biotechnology company stock worth $ 2,120,000 after purchasing an additional 248,819 shares during the last quarter. Portolan Capital Management LLC increased its stake in shares of Applied Genetic Technologies by 18.0% during the 1st quarter. Portolan Capital Management LLC now owns 1,605,599 shares of the biotechnology company stock worth $ 1,718,000 after purchasing an additional 244,895 shares during the last quarter. Millennium Management LLC increased its stake in shares of Applied Genetic Technologies by 26.0% during the 4th quarter. Millennium Management LLC now owns 1,533,193 shares of the biotechnology company stock worth $ 2,913,000 after purchasing an additional 316,276 shares during the last quarter. Finally, BlackRock Inc. increased its stake in shares of Applied Genetic Technologies by 6.4% during the 4th quarter. BlackRock Inc. now owns 1,105,950 shares of the biotechnology company stock worth $ 2,101,000 after purchasing an additional 66,771 shares during the last quarter. 38.03% of the stock is currently owned by hedge funds and other institutional investors.

About Applied Genetic Technologies (Get Rating)

Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in the Phase I / II clinical trials; and achromatopsia that is in Phase I / II clinical trials.

Featured Stories

Get a free copy of the Zacks research report on Applied Genetic Technologies (AGTC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Applied Genetic Technologies (NASDAQ: AGTC)



Receive News & Ratings for Applied Genetic Technologies Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Applied Genetic Technologies and related companies with MarketBeat.com’s FREE daily email newsletter.

.